Impact BioMedical (IBO): Kapitalisasi marang pendapatan
Impact BioMedical Inc (IBO) is developing a biomedical holding company based on the implementation of the 3F repellent and the sale of patents. Unique plant-based formulas that block viruses provide moderate pricing power. P/S levels on the chart demonstrate the market valuation of revenue, where the 1016.10 indicator determines this level. The company's strategy is based on licensing intellectual property to bypass direct price competition.
Impact BioMedical Inc (IBO) - rincian metrik lan laporan keuangan
- rega lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Impact BioMedical Inc|IBO - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal impactbiomedinc.com|IBO - Gunggung utang perusahaan|Rasio utang marang aset resik Impact BioMedical|IBO - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Impact BioMedical|Koefisien jangkoan perantara impactbiomedinc.com
- indikator bathi lan kelipatan valuasi:
IBO - Bathi resik perusahaan|Bathi resik sing dikarepake Impact BioMedical Inc|IBO - Rasio rega marang bathi|Prakiraan rega marang bathi Impact BioMedical, Inc.|IBO - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Impact BioMedical|IBO - Bathi operasional EBITDA|Bathi saben saham sajrone 12 wulan pungkasan Impact BioMedical|IBO - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan impactbiomedinc.com|IBO - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Impact BioMedical Inc
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:Impact BioMedical, Inc., IBO
Impact BioMedical Inc (IBO) is developing high-tech R&D capabilities in biomedicine and antiviral solutions, making revenue the key basis for assessing its scalability. The relationship between market capitalization and sales volume, represented by the price-to-sales ratio, reveals deviations of market value from the average, signaling asset overvaluation when the metric exceeds standard deviation boundaries and a probable reversion to the median.
Perusahaan pesaing
Koefisien rega marang pendapatan haleon.com|Rasio rega marang pendapatan Kenvue KVUE|VRNA - Kapitalisasi marang pendapatan|MENS - Rasio rega marang pendapatan|Rasio rega marang dodolan LGND|AMRX: Multiplikator P/S|perrigo.com (PRGO) - Multiplikator P/S|ALVO (Alvotech SA) - Multiplikator P/S|Kapitalisasi marang pendapatan Liquidia Corp (LQDA)|Kapitalisasi marang pendapatan GLPG (Galapagos Genomics)|Kapitalisasi marang volume dodolan ANIP|MannKind Corporation - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan AMPH|Pacira BioSciences, Inc. - Multiplikator P/S|SPRY: Rasio rega marang pendapatan|TBPH: Multiplikator P/S|AQST - Koefisien rega marang pendapatan|Rasio rega marang pendapatan scPharmaceuticals, Inc.|Rega marang dodolan Tectonic TECX|Rasio rega marang pendapatan Tonix Pharmaceuticals Holding Corp. (TNXP)|Kapitalisasi marang pendapatan sxtchina.com SXTC|Multiplikator P/S EPRX (Eupraxia Pharmaceuticals Inc.)|BioHarvest Sciences Inc (BHST) - Rega marang dodolan|eXoZymes Inc - Multiplikator P/S|ORMP (Oramed Pharmaceuticals) - Rasio kapitalisasi marang pendapatan|ENTX: Multiplikator P/S|HYFT - Koefisien rega marang pendapatan|ABVC (ABVC BioPharma Inc) - Multiplikator P/S|Kapitalisasi marang pendapatan Cumberland Corp (CPIX)|Multiplikator P/S QNTM|Multiplikator P/S fibrogen.com (FGEN)|Rasio rega marang pendapatan Telomir Pharmaceuticals, Inc. TELO|Rani Therapeutics Holdings - Rasio rega marang pendapatan|SNYR: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RLYB (Rallybio Corporation)|LEXX: Multiplikator P/S|PULM - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Pheton Holdings Limited|Rasio kapitalisasi marang pendapatan APM (Aptorum)|Multiplikator P/S LYRA|Kapitalisasi marang pendapatan tnfpharma.com TNFA|Multiplikator P/S YCBD (cbdMD)|Koefisien rega marang pendapatan painreform.com (PRFX)|Auris Medical - Multiplikator P/S|LIPO: Rasio rega marang pendapatan|Optinose (OPTN) - Rasio rega marang pendapatan|Rega marang dodolan Pieris Pharma (PIRS)|Rasio rega marang pendapatan Procaps Group S.A.|petrospharma.com - Rasio rega marang dodolan|Multiplikator P/S QLI|SLRN (Acelyrin Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S TFFP (TFF Pharma)
